Bolt Biotherapeutics vs Whitehawk Therapeutics
BOLT and WHWK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BOLT and WHWK compare
Whitehawk Therapeutics is the larger company, worth 15 times as much as Bolt Biotherapeutics ($172M against $11.2M).
Bolt Biotherapeutics grew revenue faster over the last twelve months (−51.3% versus −100% for Whitehawk Therapeutics).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BOLT | WHWK |
|---|---|---|
| Size and price | ||
| Market cap | $11.2M | $172M |
| Share price | $5.80 | $3.01 |
| Change, 1 year | 23.4% | 44.0% |
| Change, 5 years | −96.8% | −86.6% |
| Beta (5Y) | 0.10 | 2.36 |
| Employees | 23 | 23 |
| StockData Score | ||
| Total score | 8 | 8 |
| Valuation score | 1 | 1 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 | 1 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 4.4× | – |
| P/B | 1.3× | 0.9× (better) |
| FCF yield | – | −40.4% |
| Fair value | $5.43 | – |
| Margin of safety | −6.8% | – |
| Growth | ||
| Revenue growth (TTM) | −51.3% (better) | −100% |
| Revenue growth, 5Y average | 102% (better) | −12.6% |
| Profitability | ||
| Operating margin | −1098% | – |
| Net margin | −1034% | – |
| Return on equity | −129% | −45.0% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 2.05 | 17.38 (better) |
| Altman Z-score | −20.86 | 6.13 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | −0.27% | – |
| Shareholder yield | −0.27% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 31.0% | 75.8% |
| Held by insiders | 12.2% | 49.9% |
| Insider net buying, 12 months | $196K (better) | −$2.6M |
| Short interest, % of float | 2.8% | 8.7% |
Go deeper
- BOLT stock overview
- BOLT income statement
- BOLT valuation and score
- WHWK stock overview
- WHWK income statement
- WHWK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.